Constitutive expression of human MYC represses mRNA levels of cyclin Dl in proliferating BALB/c-3T3 fibroblasts. We expressed a series of mutant alleles of MYC and found that downregulation of cyclin Dl is distinct from previously described properties of MYC. In particular, we found that association with Max is not required for repression of cyclin Dl by MYC in vivo. Conversely, the integrity of a small amino-terminal region (amino acids 92 to 106) of MYC is critical for repression of cyclin Dl but dispensable for transformation of established RATlA cells. Runoff transcription assays showed that repression occurs at the level of transcription initiation. We cloned the promoter of the gene for human cyclin Dl and found that it lacks a canonical TATA element. Transcription starts at an initiator element similar to that of the adenovirus major late promoter; this element can be directly bound by USF in vitro. Expression of MYC represses the cyclin DI promoter via core promoter elements and antagonizes USF-mediated transactivation. Taken together, our data define a new pathway for gene regulation by MYC and show that the cyclin Dl gene is a target gene for repression by MYC.
The proto-oncogene c-myc was identified as the cellular homolog of the transforming oncogene of chicken myelocytomatosis virus MC29 (16, 79) . Expression of c-myc is tightly regulated and closely correlates with the proliferative status of a cell (19, 31, 39, 50, 80, 81) . Deregulated expression of c-myc is often observed in tumor cells (26, 73) . In both tissue culture and transgenic animals, introduction of a c-myc gene under the control of a strong constitutive promoter contributes to transformation and tumorigenesis; in some cells, it is sufficient for transformation (for a recent review, see reference 49) .
Cells that carry a constitutively expressed c-myc gene lose the ability to control cell proliferation in response to growth factors; when deprived of such factors, they show few signs of cell cycle arrest but often undergo apoptosis (24, 38) . This is illustrated by cells that express a chimeric protein containing the hormone-binding domain of the human estrogen receptor attached to the carboxy terminus of the human Myc protein.
Transformation by these MycER chimeras is tightly dependent on the addition of estrogen (21) . When exposed to estrogen, cells that carry such chimeras enter and progress through the cell cycle even in the absence of growth factors (22) . At the same time, part of the cell population undergoes apoptosis (24) . Also, constitutive expression of MYC leads, in some cells, to a characteristic shortening of the cell cycle which is not observed with other retroviral oncogenes (34, 65) .
Control of cell proliferation may be one way by which MYC contributes to cell transformation; how MYC exerts this control is, however, unclear. The gene encodes a nuclear phosphoprotein (28, 56) that binds to specific DNA sequences (termed E boxes) (10, 60) and activates transcription upon binding to DNA (3, 35, 42) . Several genes that carry E boxes have been suggested to be directly regulated by MYC (7, 8, 22, 27a, 78 (11, 12, 59) . Binding of Myc to Max is a prerequisite for both transcriptional activation (3, 5, 42) and transformation (2, 4) .
More recently, Myc has been reported to heterodimerize in vitro with two proteins that recognize initiator (Inr) elements of transcription, a helix-loop-helix protein termed TfII-I (63, 64) , and YY-1 (71) . Heterodimerization with Myc precludes these proteins from activating transcription either in vitro (63) or in transient transfection assays (71) , suggesting that MYC might repress genes via this pathway. Effects of MYC on cell proliferation and transformation might, therefore, result from either activation or repression of target genes; however, among the genes that are known to mediate progression through the cell cycle, those that are direct targets of MYC have not been identified.
Transitions in the mammalian cell cycle are thought to be mediated by complexes between a set of related kinases, termed cdk's (for cyclin-dependent kinase), and their regulatory subunits, termed cyclins (for a recent review, see reference 41). A number of cyclin genes have been identified that differ in the phase of the cell cycle in which they are expressed (for a recent review, see reference 70) . Expression of cyclin genes is often regulated at the transcriptional level (43, 48, 51, 57) . Generally, expression levels of different cyclins are high in proliferating cells (57, 82) . However, individual cyclin genes differ in their expression patterns in response to nuclear oncogenes (14, 74) , anti-oncogenes (30, 52) , and conditions such as senescence (45) , suggesting that they are not functionally equivalent. Indeed, biochemical differences between cyclins expressed early in the mammalian cell cycle have emerged (18, 25, 30, 36) . We have recently reported that constitutive expression of human MYC in BALB/c-3T3 cells results in elevated levels of both cyclin A and E mRNAs and repression of cyclin Dl mRNA (32) . Similar results have been obtained with Rat6 cells (33) and rat embryo fibroblasts (44) . Repression of cyclin Dl occurred under conditions in which expression of MYC induced no overt changes in cell cycle distribution. It occurred also in synchronized cells, demonstrating that it is independent of secondary effects of Myc on the cell cycle.
These data suggested that MYC has the ability to repress genes in addition to its transactivating functions. We show here that (i) repression of cyclin Dl by Myc does not require association with Max in vivo, (ii) it occurs on the level of transcription, (iii) it is mediated by core elements of the cyclin Dl promoter, and (iv) it antagonizes USF-mediated activation of the cyclin DI promoter. Together, these data define a novel transcriptional property of the Myc protein.
MATERIALS AND METHODS
Deletion mutagenesis. Deletions in the amino terminus of human MYC were introduced by PCR (29) into plasmid pSP65-cmyc (21) . The first PCR was done with a primer spanning the start site of translation (5'-GGGATCCGAAT TCACCATGCCCCTCAACGlT-3') and a primer introducing the deletion. The sequences of these primers were 5'-CCCGGAGCGGCGGCTCGCCGGGGGCTGCAG-3' for A45-63, 5'-CACCATGTCTGCTCGCCCGCCACCGCCGT C-3' for A\92-106, 5'-CTGGATGATGATGTlTTCCTCCCAG CAGCTC-3' for A109-126, and 5'-CTTCTCTGAGACGAG GTTlYlGATGAAGGT-3' for A128-143. A second reaction was performed with primer 5'-GCCCGGGAACATCGAYT TCTTCCTC-3', which hybridizes to a region encompassing the ClaI site near the exon II-exon III boundary and primers starting at the deletion site; these were 5'-AGCCGCCGCTC CGGGCTC-3' for A45-63, 5'-GGAGGAGACATGGTGAA C-3' for A92-106, 5'-AACATCATCATCCAGGAC-3' for A109-126, and 5'-CTCGTCTCAGAGAAGCTG-3' for A128-143. The products of both reactions were mixed together, and a third reaction was carried out with the underlined primers. PCR products corresponding to the full-length product were excised, digested with EcoRI and ClaI, and cloned into plasmid pSP65-cmyc. This strategy introduces a Kozak consensus sequence at the translation start ATG codon.
The presence of the correct mutations was verified by sequence analysis (66) . The sequence of In104 has not previously been reported; it is 5'-GTG ACC GAG CTC GAG CTC GAG CTG-3', which encodes V T E L E L E L L G (the sequence of wild-type [wt] Myc is V T E L L G; the valine is amino acid 102). In vitro transcription was carried out with SP6 polymerase, and translation was done with a reticulocyte lysate in accordance with the manufacturer's (Promega) instructions. Subsequently, the mutated MYC genes were cloned into retroviral vector pMV7 (40) .
For transient transfection assays, the MYC gene from pSP65-cmyc was inserted into the SmaI site of pUHD1O-1, a cytomegalovirus (CMV)-based expression vector (17) . CMVMyn was a kind gift of G. Prendergast and has been described previously (58) . For reporter plasmids, fragments of the cyclin DI promoter were inserted into luciferase vector pXP-1 (53 (48) , and that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was measured with a rat cDNA probe (27) . Primer extensions were carried out with 10 jig of total RNA from MS107 human diploid fibroblasts (54) . The primer has the sequence GGCTCCAGGACTTT IGC AACTTCAACAAAAC and hybridizes to nucleotides +90 to +61 in accordance with the numbering in Fig. 5 . Runoff transcription assays were done as previously described (22) ; filters were analyzed with a phosphoimager, and transcription rates were calculated as counts per minute hybridizing specifically to the cyclin DI probe relative to hybridizing to a GAPDH probe.
Western blot (immunoblot) analysis and immunoprecipitations. Immunoprecipitations were carried out with either preimmune antiserum or polyclonal anti-Max or anti-Myc serum (kind gift of G. Evan) essentially as described by Blackwood et al. (12) . Immunoprecipitates or whole-cell extracts were separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis, and the proteins were electrophoretically blotted onto polyvinylidene difluoride membranes. The membranes were then incubated with 5% skim milk-lI% bovine serum albumin-0.01% gelatin-0.02% Tween 20 in Tris-buffered saline (pH 8) for 2 h and then with anti-human Myc monoclonal antibody 9E10 or 3C7 (23) GGTCTGAG-3', and the mutated sequence E-box mut was 5'-ACCCGACTGAGTGGTCTGAG-3'. Gel shifts were carried out essentially as previously described (64) .
RESULTS
The functional domains of Myc involved in transformation have been well characterized (67, 75) . To determine whether repression of cyclin Dl by Myc is an indirect consequence of cell transformation by Myc, we compared the functional domains involved in cyclin Dl repression to those involved in cell transformation. PCR was used to delete small, evolutionarily conserved domains in the amino terminus of Myc (Fig. 1 ). In addition, we included several mutants originally described by Stone et al. (75) in our study. In each case, the presence of the mutations was verified by sequencing and in vitro translation was used to demonstrate that proteins of the expected sizes were synthesized (data not shown and Fig. 2B and 3B).
Recombinant retroviruses carrying the mutant MYC genes were generated, and BALB/c-3T3 fibroblasts were infected, selected for G418-resistant colonies, and pooled. Several hundred colonies were observed after each infection. Expression of the exogenous MYC gene was verified both by Northern blotting (data not shown) and by Western blotting with either monoclonal antibody 9E10 or 3C7 (23) ( Fig. 2B and 3B ). The Northern blotting results suggest that the levels of exogenous MYC mRNA are between 5-and 10-fold higher than those of the endogenous gene (data not shown). Western blots ( Fig. 2B and 3B) demonstrated that with the exception of mutant A45-63 (which appears to be unstable in vivo), all proteins were expressed at equal levels.
To determine levels of cyclin Dl mRNA expression in these cells, they were plated in 10% newborn calf serum at low density and allowed to grow for 48 h. At this time, RNA was harvested and the amounts of cyclin Dl and, as a control, GAPDH mRNAs were determined by Northern blotting. The results of this experiment are shown in Fig. 2A .
The results confirmed that BALB/c-3T3 cells that express clonal antibody (kind gift of Giulio Draetta) demonstrated that protein levels parallel mRNA levels in these cells (data not shown).
To determine more precisely if domains of the carboxy terminus of Myc are required for repression of cyclin DI, three additional mutant proteins originally described by Stone et al. (75) were analyzed as described above: 1n370, with an insertion of four amino acids at the start of helix 1 of the helix-loop-helix motif; A370-412, with a deletion of the helix-loop-helix domain; and A412-434, with a deletion of the leucine zipper (Fig.  1) (Fig. 3A) . One additional mutant protein, A104-136, had lost both transforming and repressing capacities, suggesting that this is due to loss of both a domain involved in Dl repression (around amino acid 104) and a domain necessary for RATlA transformation (MYC homology box II in A128-143 [ Fig. 1]) .
We conclude from these data that repression of cyclin Dl by MYC is not an indirect consequence of cell transformation by this oncogene. From a large collection of mutants, Stone et (Fig. 4A ).
This allowed us to test whether repression of cyclin Dl requires association of MycER with Max in vivo. We infected BALB/c-3T3 cells with a retrovirus expressing the MycER chimera and found that even in the absence of hormone, infected cells showed significantly lower levels of cyclin Dl mRNA than did control cells (Fig. 4B) . Addition of hydroxytamoxifen did not alter cyclin Dl expression. Addition of hydroxytamoxifen did, however, induce proliferation in both quiescent BALB/c-3T3-MycER (Fig. 4C) Fig. 5A . Cyclin Dl was induced by serum, tetradecanoyl phorbol acetate, transforming growth factor alpha, platelet-derived growth factor, and insulin in both vector-infected control (data not shown) and In104 (Fig. 5 ) cells, confirming results obtained with human fibroblasts (82) . None of the growth factors able to induce cyclin Dl in cells carrying the In104 allele of MYC was able to do so in In412-carrying cells (Fig. 5A) . Similar results were obtained with cells expressing wt MYC (data not shown). Control experiments showed that neither allele interfered with the ability of serum to induce proliferation and expression of the endogenous c-fos gene (data not shown). Repression of cyclin DI is therefore not an indirect consequence of the failure to respond to a particular growth factor critical for induction of cyclin Dl.
Runoff experiments have shown that induction of cyclin Dl mRNA by serum growth factors occurs at the level of transcription initiation (43) . We wondered whether expression of MYC blocked this increase and performed runoff experiments with control and In412-carrying cells before and 2 h after addition of serum to growth factor-deprived cells. The results (Fig. SB) isolated the promoter of the human cyclin Dl gene from a genomic library. Figure 6A shows the sequence of a promoter fragment extending 360 bp 5' of the end of the human cDNA clone. This fragment showed promoter activity in transient transfection assays with CV-1 cells (data not shown). The promoter lacks consensus TATA and CCAAT elements and contains binding sites for (among other potential sites) Egr (68a) and E2F (31a). To determine the transcription start site, primer extension analysis was carried out with RNA isolated from MS107 diploid human fibroblasts (54) (Fig. 6B) . Two major start sites were found at immediately adjacent C residues; these are located 40 bp upstream of the 5' end of the mouse cDNA clone. In addition, two very minor start sites were detected at positions -3 and +6 relative to the major start sites. The sequence surrounding the major start sites shows strong sequence homology to the Inr elements of the adenovirus major late, the terminal deoxynucleotide transferase, the N-CAM, and the CD44 promoters (Fig. 6C) (Fig. 7A) demonstrate that expression of MYC led to a three-to fivefold decrease in reporter gene expression relative to that obtained with a cotransfected internal control plasmid. In contrast, transfection of a CMV-MYN (the murine homolog of MAX) expression plasmid stimulated the cyclin Dl promoter weakly by itself; in combination with CMV-MYC, it did not significantly affect the repression of cyclin Dl by MYC (Fig. 7B) .
Similar results were obtained with several constructs that contained between 1,200 and 4 bp of the Dl promoter sequence upstream of the transcriptional start site (data not shown). In particular, insertion of a 17-bp oligonucleotide surrounding the transcription start site (-4 to +13) into a luciferase reporter vector led to a 10-fold increase in luciferase activity compared with an empty vector that was abolished by cotransfection of increasing amounts of a CMV-MYC expression plasmid (Fig. 7C ). These data show that (i) repression of cyclin Dl by MYC is controlled, at least in part, at the level of promoter activity, (ii) that MAX does not appear to contribute significantly to promoter repression by MYC, and (iii) that repression takes place through the core of the cyclin DI promoter.
To show that these transfections reflect the repression observed for the endogenous gene, we transfected the cyclin Dl promoter together with an internal control into BALB/c-3T3 cells expressing different alleles ofMYC and observed that relative luciferase activities closely paralleled mRNA levels of the endogenous cyclin Dl gene (Fig. 8) (Fig. 9A) . Activation by USF is mediated through the first 250 bp of the promoter, which do not contain anE-box element (Fig. 6A) . Coexpression ofMYC inhibited activation by USF in a dose-dependent manner (Fig. 9A ).
To test whether USF binds directly to the Inr element of the cyclin Dl promoter, gel shift experiments with partially purified USF (from HeLa cells; kind gift of Vincent Moncollin) were performed with a labelled oligonucleotide corresponding to the transcription start site. The results (Fig. 9B) showed that USF binds to the Inr element; competition within the unlabelled Dl Inr, the Inr element of the adenovirus major late promoter, and a consensusE-box element demonstrated that USF binds in a sequence-specific manner. Specific antibodies raised against USF (kind gift of Michele Sawadogo) supershifted the indicated band, confirming that the band indeed 
TdT albumin contained USF (Fig. 9C) (3, 5, 11, 42 Specific binding of USF to the cyclin DI Inr element. Partially purified USF was incubated with a labelled oligonucleotide spanning the cyclin DI Inr element either in the absence (-) or in the presence of the indicated competitor oligonucleotides. AdML, adenovirus major late promoter. (C) Anti-USF antibodies recognize a complex specifically binding to the cyclin Dl Inr element. A gel mobility shift experiment was performed as described before; after the binding reaction, the samples were incubated with the indicated dilutions of either preimmune serum (pre) or two different polyclonal sera raised against the 43-and 44-kDa forms of USF (68) . The arrows indicate the complex containing USF. expression of cyclin DI (14, 74) ; transient transfection assays showed that the amino terminus of ElA is involved in cyclin DI repression (74a). It is conceivable, therefore, that this motif mediates a protein-protein contact essential for repression of cyclin DI that is common to both Myc and EIA.
Expression of cyclin Dl can be induced by growth factors in quiescent cells (43, 48, 82) . However, its expression often does not correlate with the proliferative status of the cell. For example, expression of cyclin Dl is induced in response to the retinoblastoma protein (30, 52) and is also induced during senescence of human fibroblasts (45) . In particular, it is striking that cyclin Dl is downregulated in response to at least three nuclear oncogenes, those that encode adenovirus EIA (14, 74) , simian virus 40 large T (45a, 52), and MYC (32) . Also, Myc may affect translation of cyclin DI (62) . In the normal cell cycle, the cyclin DI protein is present during the G, phase and disappears as cells start to replicate their DNA (6) . Injection of the recombinant cyclin DI protein leads to an arrest at the G1-S boundary, suggesting that destruction of cyclin Dl is essential for cell cycle progression (53a). Also, a high level of cyclin DI expression inhibits cell proliferation (61) 
